The recent widespread success of immunotherapy methods targeting the B7-CD28 family members in a variety of malignancies, specifically the immune checkpoint B7-H3, has engendered hope that these strategies could also be applied to other types of cancer, including PTC. This evidence concerns the gene CD276 and cancer.